Tuberculosis - Annual Epidemiological Report for 2022
For 2022, the 30 countries in the European Union/European Economic Area (EU/EEA) reported a total of 36 179 tuberculosis (TB) cases (8.0 per 100 000 population).
Key facts
- For 2022, the 30 countries in the European Union/European Economic Area (EU/EEA) reported a total of 36 179 tuberculosis (TB) cases (8.0 per 100 000 population).
- The notification rate slightly increased for 2022 compared with the previous two years. Despite observing an increase, the mean annual change rate when compared to the period before 2020 reveals an overall declining trend. However, at the current rate the EU/EEA is not on track to reach the World Health Organisation’s global TB strategy of ending the TB epidemic by 2030.
- The decline in total case numbers and notification rates in 2020 and 2021 should be interpreted with caution, given the potential impact of measures put in place to mitigate the COVID-19 pandemic across the EU/EEA on TB diagnostic and clinical services and surveillance.
- Rifampicin resistance/multidrug resistance (RR/MDR) was reported for 4.9% of TB cases with drug susceptibility testing results reported. Of the MDR TB cases that underwent second-line drug susceptibility testing, pre-extensive drug resistance (pre-XDR) was reported for 26.9%, while extensive drug resistance (XDR) was reported for 10%.
- HIV status was reported by 21 countries for 73.6% of their total number of TB cases, and of TB cases with known HIV status, 4.1% were HIV-positive.
- Treatment success was achieved in 64.0% of all TB cases notified in 2021, 54.0% of HIV-co-infected TB cases notified in 2021, 52.5% of RR/MDR TB cases notified in 2020, and 22.2% of pre-XDR TB cases notified in 2020.
Download
Tuberculosis - Annual Epidemiological Report for 2022 - EN - [PDF-1.02 MB]
